**Supplementary Material**

# Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy: Primary Results From the DUET Study

Logan D. Schneider, MD[1]; Chad M. Ruoff, MD[2]; David T. Plante, MD, PhD[3]; Deborah A. Nichols, MS[4]; Teresa L. Steininger, PhD[4]; Douglas S. Fuller, MS[5]; M. Todd Kirby, PhD[5,6]; Sarah Akerman, MD[5,*]; Jessica K. Alexander, PhD[4]; Marisa Whalen, PharmD[5]; Alyssa Cairns, PhD[5]

[1]Stanford Sleep Medicine Center, Redwood City, CA, USA; [2]Mayo Clinic, Scottsdale, AZ, USA; [3]Department of Psychiatry, University of Wisconsin–Madison, Madison, WI, USA; [4]Jazz Pharmaceuticals, Palo Alto, CA, USA; [5]Jazz Pharmaceuticals, Philadelphia, PA, USA; [6]Department of Psychiatry & Health Behavior, Medical College of Georgia at Augusta University, Augusta, GA, USA

*Dr. Akerman is a former employee of Jazz Pharmaceuticals.

**Corresponding Author**
Logan D. Schneider, MD
Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences
Stanford Sleep Medicine Center
Email: logands@gmail.com

**Online Resource 1** Demographics and baseline characteristics for participants with narcolepsy who completed the study[a]

| Characteristic | NT1 (n=16) | NT2 (n=18) | Total (n=34) |
|---|---|---|---|
| **Age (years)** | | | |
| Mean (SD) | 35.6 (14.2) | 35.9 (14.7) | 35.7 (14.2) |
| Median (min, max) | 30.5 (20, 68) | 31.0 (22, 75) | 31.0 (20, 75) |
| **Sex at birth, n (%)** | | | |
| Male | 3 (18.8) | 6 (33.3) | 9 (26.5) |
| Female | 13 (81.3) | 12 (66.7) | 25 (73.5) |
| **Gender identity, n (%)** | | | |
| Male (including transgender man) | 3 (18.8) | 6 (33.3) | 9 (26.5) |
| Female (including transgender woman) | 13 (81.3) | 12 (66.7) | 25 (73.5) |
| Nonbinary | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Declined to state | 0 | 0 | 0 |
| **Participant of childbearing potential, n (%)** | | | |
| Yes | 8 (61.5) | 10 (83.3) | 18 (72.0) |
| **Race, n (%)** | | | |
| White | 10 (62.5) | 17 (94.4) | 27 (79.4) |
| Black or African American | 3 (18.8) | 1 (5.6) | 4 (11.8) |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 (12.5) | 0 | 2 (5.9) |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Multiple | 0 | 0 | 0 |
| Unknown | 1 (6.3) | 0 | 1 (2.9) |
| **Ethnicity, n (%)** | | | |
| Hispanic or Latino | 1 (6.3) | 2 (11.1) | 3 (8.8) |
| Not Hispanic or Latino | 15 (93.8) | 16 (88.9) | 31 (91.2) |
| **Body mass index (kg/m$^2$)** | | | |
| Mean (SD) | 28.9 (6.5) | 29.2 (6.0) | 29.1 (6.2) |
| Median (min, max) | 27.3 (20.0, 40.6) | 27.8 (21.7, 41.2) | 27.4 (20.0, 41.2) |
| **Oxybate type at study entry[b], n (%)** | | | |
| Naive[c] | 11 (68.8) | 15 (83.3) | 26 (76.5) |
| Low-sodium oxybate | 3 (18.8) | 1 (5.6) | 4 (11.8) |
| Sodium oxybate | 1 (6.3) | 2 (11.1) | 3 (8.8) |
| Once-nightly sodium oxybate | 1 (6.3) | 0 | 1 (2.9) |
| **Oxybate total nightly dosage at screening[d] (g)** | | | |
| Mean (SD) | 6.5 (0.71) | 7.7 (1.2) | 7.0 (1.0) |
| Median (min, max) | 6.3 (6.0, 7.5) | 7.0 (7.0, 9.0) | 7.0 (6.0, 9.0) |
| **Any alerting agent, n (%)[e,f,g]** | 10 (62.5) | 10 (55.6) | 20 (58.8) |
| Amphetamine aspartate, amphetamine sulfate, dexamphetamine saccharate, dexamphetamine sulfate | 2 (12.5) | 5 (27.8) | 7 (20.6) |
| Methylphenidate | 3 (18.8) | 1 (5.6) | 4 (11.8) |
| Solriamfetol hydrochloride | 3 (18.8) | 1 (5.6) | 4 (11.8) |
| Pitolisant hydrochloride | 1 (6.3) | 3 (16.7) | 4 (11.8) |
| Bupropion hydrochloride | 2 (12.5) | 1 (5.6) | 3 (8.8) |
| Lisdexamfetamine dimesylate | 1 (6.3) | 1 (5.6) | 2 (5.9) |
| Dexmethylphenidate | 1 (6.3) | 0 | 1 (2.9) |
| Modafinil | 1 (6.3) | 0 | 1 (2.9) |

[a]Completer analysis set includes all participants who enrolled in the study, took their prescribed LXB regimen for ≥1 night after the BL period, completed the SDP, and completed the PSG EOT visit.
[b]Participants taking oxybate at study entry included n=4 (NT1) and n=3 (NT2).
[c]No oxybate use within 2 weeks of entering the study.
[d]For the 7 participants who were taking an oxybate at screening and prior to washout.
[e]Participants could have been taking multiple different alerting medications.
[f]It is not known whether these agents were prescribed for excessive sleepiness, narcolepsy, and/or another condition.
[g]Concomitant medications had a stop date on or after date of first dose of study intervention or were ongoing.
BL, baseline; EOT, end of treatment; LXB, low-sodium oxybate; max, maximum; min, minimum; NT1, narcolepsy type 1; NT2, narcolepsy type 2; PSG, polysomnography; SD, standard deviation.